Ironwood Pharmaceuticals Q2 revenue beats expectations

Ironwood Pharmaceuticals

07/08/2025 12:15

Overview

Ironwood Q2 2025 revenue of $85.2 mln beats analyst expectations, per LSEG data

Adjusted EBITDA for Q2 2025 exceeds estimates, reflecting improved operational efficiency

LINZESS U.S. net sales grow 17% yr/yr, driven by increased prescription demand

Outlook

Ironwood maintains 2025 guidance for LINZESS net sales at $800-$850 mln

Company expects 2025 total revenue between $260 mln and $290 mln

Ironwood anticipates adjusted EBITDA to exceed $105 mln in 2025

Company plans FDA alignment on apraglutide Phase 3 trial in Q4 2025

Result Drivers

LINZESS SALES GROWTH - LINZESS U.S. net sales rose 17% year-over-year to $248 mln in Q2 2025, driven by a 10% increase in prescription demand, according to CEO Tom McCourt

EUTRX DEMAND - EUTRx demand grew by 10% year-over-year, contributing to LINZESS's performance, as stated by CEO Tom McCourt

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$85.24 mln
$60.80 mln (4 Analysts)
Q2 EPS
$0.14
Q2 Adjusted Net Income
Beat
$23.62 mln
$6.15 mln (2 Analysts)
Q2 Net Income
$23.60 mln
Q2 Adjusted EBITDA
Beat
$50.10 mln
$18.80 mln (3 Analysts)
Q2 Basic EPS
$0.15


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Ironwood Pharmaceuticals Inc is $1.00, about 19.5% above its August 6 closing price of $0.81

The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release: ID:nBw5Cz9Rxa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)